HARTMANN financial year 2021 characterized by coronavirus and progress in the Transformation Program

• Sales and earnings decline due to pandemic
• Transformation Program makes considerable progress with the launch of new products in the market and extensive investments in production facilities and infrastructure
• Outlook for 2022: sales and earnings down; impact of armed conflict in Ukraine not yet quantifiable

Heidenheim, March 22, 2022. For the HARTMANN GROUP, the 2021 financial year was again dominated by the strong impact of the coronavirus and progress with the Transformation Program. The expected decline in key financial figures is mainly due to the pandemic. The pandemic-related extraordinary demand for disinfectants and personal protective equipment subsided as our customers meanwhile had large supplies on stock. There continued to be a reduced market with low bed occupancy rates in medical facilities and only a gradual increase in the number of surgeries and visits to doctors and pharmacies. Significantly higher material and transport costs also had an impact. By contrast, the strategic Transformation Program had a very positive impact on Group earnings.

HARTMANN's Group sales in 2021 were EUR 2,301.8 million. This corresponds to an expected moderate organic decline in sales of -5.2% compared to the previous year. The key earnings figure of adjusted EBITDA decreased by -17.7% to EUR 240.6 million (previous year: EUR 292.4 million) and was therefore within the forecast range as published. HARTMANN adheres to the principle of a dividend policy focused on continuity. The proposed dividend is unchanged from the previous year at EUR 8.00 per share.

• Infection Management: Demand has declined due to customers with large supplies on stock.
• Incontinence Management: The persistence of low bed occupancy rates in hospitals and nursing homes resulted in subdued demand.
• Wound Care¹: Despite growth, the wound care market remains significantly below the market development prior to the coronavirus pandemic.
• Complementary Group Divisions¹: KNEIPP continued to successfully serve the trend towards greater health awareness; KOB recorded growth in compression bandages.

¹The names of these business segments were altered in 2021.

For the 2022 financial year, HARTMANN continues to expect a moderate organic decline in sales and a decline in adjusted EBITDA in the range of EUR 190 to 230 million. Due to the ongoing pandemic, there is a high degree of uncertainty in this forecast. In addition, possible effects of the Russia-Ukraine conflict are not yet quantifiable and therefore not included in the outlook.

HARTMANN condemns any aggression that endangers people’s lives and health. HARTMANN is offering aid through cash and non-cash donations to Ukraine as well as neighboring countries who are providing shelter for the large number of refugees. In addition, the Company is supporting the family members of Ukrainians employed by the Company who have fled.

The annual report and financial statements for financial year 2021 can be foundunder the investor relations section.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.